Advanced search

News (334)

Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS Regimen in Patients with Relapsed, Refractory Diffuse Large B-cell Lymphoma	Mar. 13	AQ
Pfizer: positive results from lymphoma trial	Mar. 12	CF
Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)	Mar. 12	BU
Pfizer : Oncology Innovation Day Transcript	Mar. 03	PU
Transcript : Pfizer Inc. - Special Call	Feb. 29
Pfizer : Oncology Innovation Day Presentation	Feb. 28	PU
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer	Feb. 06	GL
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer	Feb. 06	AQ
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer	Feb. 02	BU
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer	Feb. 02	GL
European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer	Jan. 26	BU
Pfizer, Inc. - TIVDAK Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer	Jan. 10	AQ
Pfizer's licence application accepted for priority review of Tivdak	Jan. 09	AN
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer	Jan. 09	BU
TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer	Jan. 09	BU
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer	Jan. 09	GL
Pfizer Inc. - PADCEV with KEYTRUDA Approved by FDA as the First and Only ADC plus PD-1 to Treat Advanced Bladder Cancer	Dec. 18	AQ
Astellas Pharma Inc. - PADCEV with KEYTRUDA Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer	Dec. 18	AQ
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer	Dec. 15	BU
Seagen Inc. Announces Management Changes	Dec. 14	CI
Seagen Inc. - ADCETRIS plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma	Dec. 11	AQ
ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma	Dec. 10	BU
Seagen Inc. - TUKYSA in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer	Dec. 07	AQ
TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer	Dec. 06	BU
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer	Nov. 30	BU
Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting	Nov. 03	BU
New Data for ADCETRIS® (brentuximab vedotin) with Immunotherapy Combination in Hodgkin Lymphoma to be Featured at 2023 ASH Annual Meeting, and Seagen to Unveil Novel CD30-Directed Antibody-Drug Conjugate	Nov. 02	BU
Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress	Nov. 01	BU
Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer	23-10-22	BU
TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial	23-10-22	BU
Seagen to Highlight Overall Survival Data for PADCEV and TIVDAK during Presidential Symposium at ESMO Congress 2023	23-10-17	AQ
Seagen to Highlight Overall Survival Data for PADCEV® and TIVDAK® during Presidential Symposium at ESMO Congress 2023	23-10-16	BU
Seagen Inc. - PADCEV and KEYTRUDA Significantly Improve Overall Survival and Progression-Free Survival in Patients with Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial	23-09-25	AQ
PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial	23-09-22	BU
Genmab and Seagen Announce That TIVDAK Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy	23-09-05	AQ
Seagen and Genmab Announce TIVDAK Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone	23-09-05	AQ
Genmab, Seagen say Tivdak cervical cancer trial met overall survival endpoint	23-09-04	RE
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy	23-09-04	BU
Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone	23-09-04	BU
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy	23-09-04	GL
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy	23-09-04	AQ
Seagen Phase 3 Trial of TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-trastuzumab emtansine Meets Primary Endpoint of Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer	23-08-16	BU
Seagen Second Quarter 2023 Financial Results Demonstrate Exceptional Commercial Performance Driving Record Product Sales with Strong Growth and Momentum	23-08-02	BU
Seagen Inc. - Phase 3 Trial of ADCETRIS with Modified Chemo Regimen Shows Non-Inferiority with Unprecedented 3-Year Progression Free Survival of 94.9% vs Less Tolerable International Standard of Care in Advanced Classical Hodgkin Lymphoma	23-06-21	AQ
Phase 3 Trial of ADCETRIS® (brentuximab vedotin) with Modified Chemo Regimen Shows Non-Inferiority with Unprecedented 3-Year Progression Free Survival of 94.9% vs Less Tolerable International Standard of Care in Advanced Classical Hodgkin Lymphoma	23-06-20	BU

1234NextSee all

Companies (20)

COMPAGNIE FINANCIERE RICHEMONT 88 443 M $

Compagnie Financière Richemont SA is a world leader in luxury products. Net sales break down by family of products as follows: - jewelry items (42.2%): the brands Cartier (world No. 1 in jewelry), Van Cleef & Arpels, and Giampiero Bodino; - luxury watch ...

COMPAGNIE FINANCIERE RICHEMONT 88 443 M $

L'ORÉAL 264 B $

L'Oréal is the world leading cosmetic group. The group offers skincare products (39.9% of sales), makeup products (19.7%), haircare products (15.4%), fragrances (12.6%), hair colouring products (8.3%) and other (4,1%). Net sales break down by family of pr ...

ROGERS COMMUNICATIONS INC. 21 510 M $

Rogers Communications Inc. is a wireless, cable, and media company. The Company provides connectivity and entertainment to Canadian consumers and businesses across the country. The Company also has a portfolio of media properties, which includes sports me ...

ROGERS COMMUNICATIONS INC. 21 510 M $

NORFOLK METALS LIMITED 4 M $

Norfolk Metals Limited is an Australia-based mineral exploration and resource development Company. The Company is a gold and uranium focused explorer with assets located in Tasmania and South Australia respectively. It holds interest in Roger River Projec ...

PETROGAS COMPANY 2 M $

PetroGas Company has working interests in certain oil and gas properties. The Company's properties include Ellis County, Hemphill County, Madison County, Shelby County and Emergy County. Ellis County is an overriding royalty interest (ORR), which is locat ...

QC COPPER AND GOLD INC. 18 M $

QC Copper and Gold Inc. is engaged in the exploration, development and production of exploration and evaluation assets in Canada. It is focused on developing copper projects in the Chapais-Chibougamau region. The Companyâs projects include Opemiska Copp ...

TOD'S S.P.A. 1 537 M $

Tod's SpA is an Italy-based holding company. The Company, through its subsidiaries, is primarily engaged in creation, production and distribution of shoes, leather goods and accessories, apparel. The Company operates in the luxury sector under brands, suc ...

TOD'S S.P.A. 1 537 M $

12Next

Insiders

Roger Dansey

Presently, Roger D. Dansey occupies the position of Chief Medical Officer for Seagen Inc. In the past Dr. Dansey held the position of Vice President-Oncology Clinical Research at Gilead Sciences, Inc. and SVP & Head-Therapeutic Area at Merck Research Laboratories Massachusetts LLC. Dr. Dansey received a doctorate from the University of the Witwatersrand.

Michele Dansey

Terence Dansey

Rick E. Dansey

Rick E.
Dansey has a current job as a Director at netElastic Systems, Inc.

Roger currently works at Comefly Outdoor Co. Ltd., as Director from 2021.

Roger

No results for this search